Photo of Tomasz M. Beer, M.D., F.A.C.P.

Tomasz M. Beer M.D., F.A.C.P.

    • Professor of Medicine, Division of Hematology/Medical Oncology School of Medicine
    • Grover C. Bagby Chair of Prostate Cancer Research
    • Cancer Biology Graduate Program School of Medicine

Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.

Read more

Education

  • M.D., The Johns Hopkins University, Baltimore Maryland 1991
  • Residency:

    • Oregon Health & Science University, Portland
  • Fellowship:

    • Hematology and medical oncology, Oregon Health & Science University, Portland
  • Certifications:

    • Oncology

Memberships and associations

  • American College of Physicians
  • Oregon Medical Association
  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Association for Cancer Research
  • Southwest Oncology Group
  • American Urological Association
  • Radiation Therapy Oncology Group

Publications

  • "Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer : Data from PREVAIL and AFFIRM trials." Prostate Cancer and Prostatic Diseases In: , Vol. 20, No. 1, 01.03.2017, p. 110-116.
  • "Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer : post hoc analysis of PREVAIL." Prostate Cancer and Prostatic Diseases In: , 24.01.2017.
  • "Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer." Journal of Clinical Oncology  In: , Vol. 35, No. 1, 01.01.2017, p. 40-47.
  • "Taking Care of Our Friends and Neighbors : DeVita's The Death of Cancer and the Challenge of Letting Go." JAMA oncology  In: , Vol. 3, No. 1, 01.01.2017, p. 16-17.
  • "Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?" JAMA oncology In: , Vol. 3, No. 1, 01.01.2017, p. 11-12.
  • "Falls and Frailty in Prostate Cancer Survivors : Current, Past, and Never Users of Androgen Deprivation Therapy." Journal of the American Geriatrics Society In: , 2017.
  • "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma." Journal for ImmunoTherapy of Cancer In: , Vol. 4, No. 1, 92, 20.12.2016.
  • "Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial." Clinical Genitourinary Cancer In: , 14.12.2016.
  • "Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer : Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team." European Urology Focus In: , Vol. 2, No. 5, 01.12.2016, p. 469-471.
  • "Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate : A Randomized Controlled Trial." Nutrition and Cancer  In: , Vol. 68, No. 8, 16.11.2016, p. 1309-1319.
  • "Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer : 10-year follow-up and immune correlates." Anti-Cancer Drugs In: , 23.09.2016.
  • "Perpetuating effects of androgen deficiency on insulin resistance." International Journal of Obesity In: , 13.09.2016.
  • "Raising the bar for therapeutic trials in advanced prostate cancer." Journal of Clinical Oncology In: , Vol. 34, No. 25, 01.09.2016, p. 2958-2960.
  • "Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer." Oncotarget In: , Vol. 7, No. 33, 01.08.2016, p. 52810-52817.
  • "Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer : A post-hoc analysis of the placebo-controlled PREVAIL trial." International Journal of Urology  In: , Vol. 23, No. 5, 01.05.2016, p. 395-403.
  • "Trial design and objectives for castration-resistant prostate cancer : Updated recommendations from the prostate cancer clinical trials working group 3." Journal of Clinical Oncology In: , Vol. 34, No. 12, 20.04.2016, p. 1402-1418.
  • "Treatment of nonmetastatic castration-resistant prostate cancer." ONCOLOGY (United States) In: , Vol. 30, No. 4, 15.04.2016.
  • "Treatment of Nonmetastatic Castration-Resistant Prostate Cancer." Oncology (Williston Park, N.Y.) In: , Vol. 30, No. 4, 01.04.2016, p. 336-344.
  • "Metastatic prostate cancer in 2015 : The new and the old that is new again." Nature Reviews Clinical Oncology In: , Vol. 13, No. 2, 01.02.2016, p. 73-74.
  • "Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer : Results from PREVAIL." Annals of Oncology In: , Vol. 27, No. 2, mdv542, 01.02.2016, p. 286-294.
  • "The PREVAIL Study : Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer." European Urology  In: , 2016.
  • "Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study." European Urology  In: , 2016.
  • "Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor." Oncotarget In: , Vol. 7, No. 26, 2016, p. 40690.
  • "Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention : Double-blind randomised study of pre-prostatectomy celecoxib or placebo." BJU International  In: , 2016.
  • "Benefits of partnered strength training for prostate cancer survivors and spouses : results from a randomized controlled trial of the Exercising Together project." Journal of Cancer Survivorship In: , 29.12.2015, p. 1-12.
  • "Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer." European Urology In: , Vol. 68, No. 5, 01.11.2015, p. 795-801.
  • "The Effects of Partnered Exercise on Physical Intimacy in Couples Coping With Prostate Cancer." Health Psychology In: , 12.10.2015.
  • "Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate : Post hoc analysis of study COU-AA-302." European Urology In: , Vol. 68, No. 4, 01.10.2015, p. 570-577.
  • "Should docetaxel be administered earlier in prostate cancer therapy?" Expert Review of Anticancer Therapy In: , Vol. 15, No. 9, 02.09.2015, p. 977-979.
  • "Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients." Clinical Genitourinary Cancer  In: , Vol. 13, No. 4, 01.08.2015, p. e217-e221.

Additional information

Edit profile